Randomized, prospective double-blind placebo controlled study for the evaluation of the number, duration and severity of Upper Respiratory Tract Infections in children with risk of recurrence after standard treatment with bacterial lysates Paspat 3 mg tablets, over an observation period of six months.
Phase of Trial: Phase III
Latest Information Update: 21 Feb 2018
At a glance
- Drugs LW 50020 (Primary)
- Indications Bacteroides infections
- Focus Therapeutic Use
- Acronyms ICASP
- Sponsors Daiichi Sankyo Company
- 21 Feb 2018 Status changed to recruiting.
- 07 Oct 2017 New trial record